Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

Add BPTH Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/18/2017 4:16:29 PM - Followers: 46 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the beginning of phase 2 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in the 4th quarter of 2017.

CML combination drug safety study with Sprycel (Dasatinib) for BP1001 has begun at MD Anderson.

Patent protection for their neutral lipid delivery system has been allowed.
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.

While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional funds  the company has 6+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:!/4292/presentation/2610

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $1.50 target, Stonegate Capital Blackstone $4. Thompson Reuters rates BPTH as out perform with a target of $3.25. MSCI raised BPTH from 1 to 3.

Zack's rating now equals hold.

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#3304   Gp, The plan is to VOTE OUT the SJSTOCKSHARK 11/18/17 04:16:29 PM
#3303   Snug9, I have also voted and voted the Gpheart2016 11/18/17 11:52:48 AM
#3302   Agree 100%! dmoffat 11/17/17 09:18:54 PM
#3301   GpHeart, I just had the privilege of voting Snug9 11/17/17 06:24:33 PM
#3300   HEAR! HEAR! longinvesting 11/17/17 01:32:16 PM
#3299   YES there is a choice. VOTE NO on longinvesting 11/17/17 01:30:44 PM
#3298   News More stock sold: SJSTOCKSHARK 11/17/17 09:38:06 AM
#3297   I do not see how the reverse split SJSTOCKSHARK 11/16/17 10:54:54 PM
#3296   Dmoffat, I don’t disagree. Buleeeeeve me. Gpheart2016 11/16/17 04:15:16 PM
#3295   I think we are on the verge of dmoffat 11/16/17 01:08:46 PM
#3294   Sorry if I over interpreted your comments. I Gpheart2016 11/16/17 11:54:17 AM
#3293   I don’t know what part of my post dmoffat 11/16/17 11:43:20 AM
#3292   Hey, longinvesting and dmoffat: I’m one of Gpheart2016 11/16/17 11:29:14 AM
#3291   Just a couple years ago bpth raised funds dmoffat 11/15/17 08:56:21 PM
#3290   Word, I still own a not insignificant quantity Snug9 11/15/17 06:35:33 PM
#3289   To the person who wrote that PN said longinvesting 11/15/17 06:02:54 PM
#3288   But you still own shares, Snug9? wordlender 11/14/17 09:58:26 PM
#3287   ADVFN, I was once an optimist as far Snug9 11/14/17 08:09:49 PM
#3286   Mr bobster, were you able to access the Gpheart2016 11/14/17 06:59:19 PM
#3285   Lol, that’s what I was thinking too! dmoffat 11/14/17 05:47:16 PM
#3284   thomscm2, I don't know how long you've had Brettj 11/14/17 04:42:42 PM
#3283   PN says January. Is that too long to ADVFN_thomscm2 11/14/17 04:18:44 PM
#3282   Irrelevant. Until PN leaves or miraculously finishes something dmoffat 11/13/17 08:31:20 PM
#3281   Can any one tell me if this news Mt Bobster 11/13/17 05:52:18 PM
#3280   Yet somehow they’ll still deserve excessive pay and dmoffat 11/13/17 11:45:02 AM
#3279   Bio-Path Holdings (NASDAQ:BPTH) price target lowered to $1.50 Brettj 11/13/17 10:16:20 AM
#3278   The confusing answer that Peter gives to Yi Gpheart2016 11/11/17 12:08:15 PM
#3277   More conference info: SJSTOCKSHARK 11/11/17 09:45:29 AM
#3276   f Executive Officer allbetson 11/11/17 09:40:38 AM
#3275   November 10th, 2017 Mt Bobster 11/11/17 01:52:13 AM
#3274   So in other words "we will adjust it Pat Torney 11/10/17 02:32:56 PM
#3273   Excerpt from proxy materials saying the stock based wordlender 11/10/17 12:09:55 PM
#3272   So I was talking to a good friend Pat Torney 11/10/17 10:40:56 AM
#3271   Did anyone get anything new from the conference Gpheart2016 11/10/17 10:31:17 AM
#3270   We have 19 dosed but not evaluable. It SJSTOCKSHARK 11/10/17 10:21:44 AM
#3269   That’s what I keep telling myself! dmoffat 11/09/17 07:44:15 PM
#3268   Word, I agree with your sentiments and your Snug9 11/09/17 07:32:02 PM
#3267   Well said, wordlender. That expresses my view exactly. Gpheart2016 11/09/17 06:49:42 PM
#3266   Good news could come any day, and if wordlender 11/09/17 03:37:56 PM
#3265   What I don't understand here is we all iloveu2 11/08/17 06:52:47 PM
#3264   I was amusing myself with my reply. I dmoffat 11/08/17 05:53:33 PM
#3263   I am afraid that's wishful thinking.......At least consider longinvesting 11/08/17 05:25:58 PM
#3262   I am sorry but you probably did not longinvesting 11/08/17 05:18:24 PM
#3261   Couldn't agree more. If the 19 patients Runninonempty 11/08/17 02:49:06 PM
#3260   Unfortuanately GP, while the 10:1 RS is a Snug9 11/08/17 02:38:47 PM
#3259   You are right , Pat. We can only Gpheart2016 11/08/17 01:53:42 PM
#3258   Sweet, I will have 10 times as many dmoffat 11/08/17 01:08:27 PM
#3257   GP, I don't think we are able to Pat Torney 11/08/17 12:51:42 PM
#3256   Never posted here but have been reading the K-Diddy 11/08/17 11:53:55 AM
#3255   Longinvesting, I just voted “AGAINST” on all of Snug9 11/08/17 11:43:39 AM